Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review

@article{Hert2008TypicalAA,
  title={Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review},
  author={Marc De Hert and Vincent Schreurs and Kim Katharine Maria Sweers and Dominique Van Eyck and Linda Hanssens and Sebastjan {\vS}inko and Martien Wampers and Andr{\'e} Scheen and Joseph Peuskens and Ruud Van Winkel},
  journal={Schizophrenia Research},
  year={2008},
  volume={101},
  pages={295-303}
}
UNLABELLED The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at the onset of the disorder and specifically no data on patients treated in the era when only first-generation antipsychotics were available. METHODS Data from a historic cohort of consecutively admitted first-episode patients with schizophrenia treated with first-generation antipsychotics… Expand
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
TLDR
It is suggested that in first-episode, partially antipsychotic-naive patients, the baseline prevalence of metabolic syndrome appears to be no higher than that in the general population, but serious underlying individual risk factors nevertheless existed. Expand
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
TLDR
It is indicated that the first year of antipsychotic treatment is a critical period for weight gain and metabolic changes and Identification of weight gain patterns may help to inform studies that aim to prevent or mitigate the metabolic adverse events associated with antipsychotics. Expand
Assessment of Long Term Metabolic Effects of Atypical Antipsychotics in Schizophrenia Patients
TLDR
The results emphasize the highly dynamic character of the metabolic syndrome even in chronic schizophrenia patients with fixed SGA regimen and suggest the normalization of MetS is a possibility that should not ignored. Expand
Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
TLDR
The prevalence of MetS steadily increased with the continuous use of SGAs in patients with schizophrenia who had been maintained on a fixed SGA regimen for more than a year, and about a quarter of the patients were able to recover naturally without specific measurements. Expand
Metabolic syndrome in schizophrenia: A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India
TLDR
Use of antipsychotics increases the risk of developing hyperlipidemia and MS in patients of schizophrenia and related disorders, emphasizing the need for regular monitoring of various metabolic parameters in patients on antipsychotic medications. Expand
Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.
TLDR
There is a significantly lower cardiovascular risk in early SZ than in chronic SZ, and both diabetes and pre-diabetes appear uncommon in the early stages, especially in UM. Expand
The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs
The objective of this crosssectional study was to estimate the prevalence of metabolic disorders and hypertension in patients with schizophrenia and to compare prevalence between patients treatedExpand
A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
ABSTRACT OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the mostExpand
Metabolic syndrome in schizophrenia: how much is attributable to drug treatment? -
TLDR
Both olanzapine and quetiapine were found to cause comparable metabolic derangement and metabolic syndrome. Expand
Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study
TLDR
The prevalence of the abnormal metabolic measures was high in this sample, but those on SGA showed a significantly higher prevalence of abnormal body mass index and BP than those on FGA. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
TLDR
The current data suggest that metabolic abnormalities are an inherent part of schizophrenic illness, as they are already present in first-episode patients, and considerably increased with increasing duration of illness. Expand
Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
TLDR
Clinicians should be aware of these risks, choose an antipsychotic that causes less weight gain and should monitor these patients carefully, and recommend prophylactic measures as diet restriction and physical activities. Expand
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
TLDR
The metabolic syndrome is highly prevalent in US schizophrenia patients and represents an enormous source of cardiovascular risk, especially for women, so clinical attention must be given to monitoring for this syndrome, and minimizing metabolic risks associated with antipsychotic treatment. Expand
Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
TLDR
The current diagnosis of metabolic problems, and a review of antipsychotic-related metabolic problems (diabetes, lipid abnormalities and the metabolic syndrome), as well as guidelines for the screening and management of metabolic abnormalities in people treated with antipsychotics are provided. Expand
Metabolic syndrome in patients with schizophrenia.
TLDR
The results suggest that metabolic syndrome is common among patients with schizophrenia, and it may be far more common than in general populations. Expand
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
TLDR
Both the rate and incidence of clinically relevant metabolic syndrome differ according to the choice of antipsychotic agent, and the association between metabolic syndrome and treatment warrants careful consideration in the choices of antippsychotic agents. Expand
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study
TLDR
CHD risk and MS prevalences among patients with schizophrenia treated with antipsychotics were in the same range as the Spanish general population 10 to 15 years older. Expand
Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study
TLDR
Thai schizophrenic patients are likely to develop MetS and their metabolic abnormalities may progress rapidly and fulfill the MetS definition within a year of follow-up, support the importance of assessing and monitoring metabolic syndrome in schizophrenia patients. Expand
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
TLDR
The metabolic syndrome is highly prevalent in this large cohort of schizophrenia patients and is strongly associated with a poor self-rating of physical health and increased somatic preoccupation, underscore the need for mental health practitioners to take an active role in the health monitoring of patients with schizophrenia to minimize the impact of medical comorbidity. Expand
Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.
TLDR
These data confirm the high prevalence of metabolic syndrome in patients receiving second-generation anti-psychotics, indicate that metabolic syndrome doubles the 10-year risk of CHD events in this population, and emphasize the importance of the "hypertriglyceridemic waist" for the identification of psychiatric patients at high risk ofCHD. Expand
...
1
2
3
4
5
...